Pharmacokinetic and Pharmacodynamic Bio-Similarity of ADL-018 to Innovator Omalizumab: A Randomized Study in Healthy Adults.
This randomized controlled trial evaluated the pharmacokinetic and pharmacodynamic bio-similarity of ADL-018, a biosimilar to omalizumab, in 306 healthy adults.
Why it matters
The findings support the use of ADL-018 as a biosimilar to omalizumab, indicating it may provide similar efficacy and safety profiles, which is crucial for treatment decisions in allergy management.